Genomic Profiling and New Immunotherapies: An Oncologist’s Perspective


The purpose of this lecture is to give pathologists a clinical perspective on how oncologists use molecular testing and biomarkers for therapeutic implications. A review of several trials focuses on tests and therapies that have been FDA approved or appear promising for future approval.

Originally presented on February 7, 2018 in Park City, Utah.

Lecture Presenter

Jonathan Whisenant, MD

Jonathan Whisenant, MD

Associate Professor (Clinical), Division of Oncology, Department of Medicine
University of Utah School of Medicine

Jonathan Whisenant, M.D., is an Associate Professor (Clinical) in the Division of Oncology, Department of Medicine, at the University of Utah, School of Medicine. His clinical practice is based at the Huntsman Cancer Institute. Dr. Whisenant is a specialist in medical oncology with a primary area of interest in cancers of the gastrointestinal system.

Dr. Whisenant received his medical degree from the University of California, San Francisco. He went on to complete an Internal Medicine residency at the University of Colorado in Denver, Colorado prior to returning to California where he completed a joint fellowship in Hematology and Medical Oncology at the University of California, San Francisco.

Dr. Whisenant relocated to Utah in 2005 and has been practicing in the Salt Lake Valley with Utah Cancer Specialists. He is board certified in Medical Oncology and is a member of the American Society of Clinical Oncology and the Society of Utah Medical Oncologists.

Dr. Whisenant joined the Huntsman Cancer Institute in January 2016 where his clinical practice will focus on treating gastrointestinal malignancies with a primary research interest in gastrointestinal malignancies and developmental therapeutics.


After this presentation, participants will be able to:

  • Review the standard of care molecular tests for GI cancers
  • Identify promising targeted therapies in GI cancers not yet FDA approved
  • Discuss useful or promising immunotherapies in GI cancers

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories